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Introduction
The dystrophin-associated glycoprotein complex
(DAGPC) is part of the cytoskeleton. Dustin and
Brion (1988) distinguished microfilaments, inter-
mediate filaments, and microtubules as cytoskeletal
components. The functions of these proteins in-
clude cell contractility, organisation of cell shape,
and intracellular transport (Denk et al., 1990). The
DAGPC is part of the microfilaments. It combines
the inner cytoskeleton with the extracellular matrix
(Worton, 1995). The complex includes dystrophin,
α-, β-, and y-sarcoglycan and α- and β-dystrogly-
can. Dystrophin connects actin filaments in the cy-
toplasm with α-, β-, and y-sarcoglycan and
β-dystroglycan in the basal lamina. These proteins
and laminin in the extracellular matrix are sup-
ported by α-dystroglycan (Kreis and Vale, 1999). 
The dystrophin-associated glycoprotein com-
plex are expressed in different tissues, such as the
brain, kidneys, and liver (Renley et al., 1998;
Rafael et al., 1999; Loh et al., 2001). There is much
information about this complex in striated muscle
cells (Ervasti and Campbell, 1991; Ervasti and
Campbell 1993; Ervasti and Cambell, 1993). Dif-
ferent muscle diseases result in varying expression
of the proteins of this complex (Dubowitz, 1992;
McNally et al., 1996; Duclos et al., 1998; Duggan
et al., 1998; Hack et al., 1989). 
The most important disease of this complex is
Duchenne muscular dystrophy. It is a disease with
decreased expression of dystrophin. Duchenne
muscular dystrophy is a severe form of the disease.
A milder form is Becker muscular dystrophy,
which is also a consequence of decreased expres-
sion of dystrophin, but not to such a low level. The
diseases illustrate that not all proteins of the
DAGPC are expressed equally; indeed, differential
expression is responsible for different diseases.
Some data exist about cytoskeletal proteins in
the liver. Loh et al., (2001) detected increased ex-
pression of dystrophin-associated protein in brain,
kidney, and liver. Bedossa et al. (2002) investigated
dystroglycan expression in hepatic stellate cells
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Abstract
Activation of Ito cells and their metamorphosis into myofibroblasts is the primary process in fibrotic remodelling in chronic
liver disease. The dystrophin-associated glycoprotein complex (DAGPC) is part of the cytoskeleton of muscle cells and is
also expressed in other tissues. Because of its differential expression in muscle degeneration, we investigated this complex
in normal healthy liver tissue and tissue with chronic liver degeneration in dogs and cats to gain information about cell alter-
ations in chronic liver disease. In normal liver tissue from both species, we found mild expression of dystrophin 1 and β-dy-
stroglycan, especially in Ito cells. Dystrophin 2 and y-sarcoglycan showed no expression. In chronic degenerative liver
diseases, we found increased expression of dystrophin 1 and β-dystroglycan in Ito cells in dogs and cats. We suggest that this
increased protein expression is an early sign of the metamorphosis of Ito cells in the beginning of chronic degenerative liver
disease.
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(also known as Ito cells). They found deposits of
β-dystroglycan in hepatic stellate cells, but not on
hepatocytes. Maher et al. (1988) detected expres-
sion of laminin in rat liver lipocytes. Gesemann et
al. (1998) found low expression of dystroglycan in
liver cells. 
There are only few reports about DAGPC pro-
teins and liver diseases (Denk and Lackinger, 1986;
Denk et al.,1986; Denk et al., 1990). Currently,
there are no data available about the expression of
DAGPC in liver cells in dogs and cats. 
Here, we report the expression of dystrophin-
associated glycoproteins in normal liver tissue and
chronic degenerative liver diseases in dogs and
cats. The aim of the study was to describe Ito cell
metamorphosis, an early and important step in the
fibrotic remodelling process of chronic liver dis-
eases. First, activated Ito cells transform into my-
ofibroblasts and later to fibroblasts. Myofibroblasts
are contractile and need cytoskeleton proteins for
their function (Gressner, 1991; Bachem et al.,
1992).
Materials and methods
From patients treated at the Small Animal Clinic,
Institute of Veterinary Medicine of the University
of Goettingen, liver biopsies were taken. We col-
lected samples from two healthy dogs and two
healthy cats and eight dogs and eight cats with
chronic degenerative liver diseases. The diagnoses
of liver diseases were made from clinical symp-
toms, clinical biochemistry, and histopathology. 
Biopsies were taken under general anesthesia
(cats, ketamine and acepromacine; dogs, lev-
omethadon and acepromacine) using “truecut”
biopsy needles (Surgivet) or during a laparatomy.
One part of each biopsy was taken for further di-
agnosis and another was snap-frozen in liquid ni-
trogen for immunohistochemistry. 
Using a cryostat (Microm Company), 8-10 µm
sections were prepared from the biopsies. Immuno-
histochemistry was performed automatically in a
Ventana NexES ICH staining module using the
Ventana Basic DAB detection kit. The following
monoclonal primary antibodies (Novocastra Com-
pany) were used: y-sarcoglycan (NCL-g-SARC,
dilution 1:50), β-dystroglycan (NCL-b-DG, dilu-
tion 1:100), dystrophin 1-rod domain (NCL-DYS1,
dilution 1:20), and dystrophin 2–C-terminus (NCL-
DYS2, dilution 1:20). Subsequently, the sections
were evaluated semi-quantitatively by light mi-
croscopy.
Results
We investigated normal liver tissue with immuno-
histochemistry for expression of y-sarcoglycan, β-
-dystroglycan, dystrophin 1 (rod domain) and
dystrophin 2 (C terminus). All immunohistochem-
istry was done with antibodies that are commonly
used for the detection of these proteins in dogs.
There is no report about the expression of these
proteins in cats. Thus, we investigated the antibod-
ies in normal muscle tissue from cats. We found
that the antibodies (from Novocastra) against y-
sarcoglycan (at 1:50), β-dystroglycan (at 1:100),
dystrophin 1 (at 1:20), and dystrophin 2 (at 1:20)
were able to detect these proteins in cat muscle
cells (Table 1). 
For the detection of the proteins in normal liver
tissue, we investigated two cats and two dogs. The
results from normal liver tissue in dogs and cats are
shown in Table 2. In healthy cats, we found no ex-
pression of dystrophin 2 or y-sarcoglycan in liver.
Expression of β-dystroglycan and dystrophin 1 was
mild. 
In total, we investigated eight cases of liver dis-
ease in cats. In all cases, the pathological diagnosis
was chronic degenerative liver disease. The diag-
nosis of degenerative liver disease was made if the
histological picture showed hydropic swelling, vac-
uolization, intracellular lipid accumulation, and
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Table 1. Usefulness of antibodies for normal muscle tissue
in cats.
Table 2. Antibody reaction in normal liver tissue in dogs and
cats.
signs of necrosis and fibrosis in liver tissue. We
found no expression of y-sarcoglycan or dystrophin
2 in any case. In all cases, we found increased ex-
pression of β-dystroglycan and dystrophin 1. The
expression of these proteins was found on some he-
patocytes, but especially on Ito cells in the perisi-
nusoidal space (Table 3; Fig. 1, 2). There was no
apparent correlation between the degree of liver de-
generation and the degree of protein expression.
In healthy dogs, we found only a mild reaction for
dystrophin 1 and β-dystroglycan. Dystrophin 2 and
y-sarcoglycan showed no reaction. Eight samples
of diseased dog livers were investigated. The
pathological diagnosis in each case was chronic de-
generative liver disease. The criteria for the diag-
nosis were the same as in cats. There was no
detectable expression of y-sarcoglycan or dys-
trophin 2 in any case. On the other hand, β-dystro-
glycan and dystrophin 1 expression was increased
on the surface of some degenerative liver cells, but
mostly on the surface of Ito cells. Similar to the re-
sults in cats, there was no apparent correlation be-
tween degree of liver degeneration and degree of
protein expression.
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Table 3. Results of immunohistochemistry (β-dystroglycan, dystrophin1) in chronic degenerated liver disease in dogs and
cats
+ = mild elevated to normal, ++ = marked elevated to normal, +++ = severe elevated to normal
Fig.1. High expression of dystrophin 1 in cat liver tissue
with marked liver cell degeneration.
Fig. 2. High expression of β-dystroglycan in cat liver tissue
with marked liver cell degeneration.
Discussion
Cytoskeletal proteins have gained increasing im-
portance since some investigators found associa-
tions between the expression of these proteins and
diseases. In Duchenne muscular dystrophy, for ex-
ample, a direct association has been shown be-
tween the expression of dystrophin and the degree
of the disease (Dubowitz, 1992). Altered expres-
sion of cytoskeleton proteins has also been associ-
ated with diseases in other organs (Denk and
Lackinger, 1985; Kunze and Rustow, 1993; Cadrin
and Martinoli, 1995; Bedossa et al., 2002). In our
investigation, we analysed changes in the expres-
sion of dystrophin-associated glycoproteins in
chronic degenerative liver tissue. The expression
of DAGP in normal murine liver cells has been de-
scribed by Durbeej et al. (1998). They found α/β-
dystroglycan at the sinusoidal face of hepatocytes
in healthy adult mice. In healthy dogs and cats, we
found only infrequent mild expression of β-dystro-
glycan on hepatocytes and on Ito cells. α-Dystro-
glycan could not be examined in dogs or cats,
because there is no known cross-reactivity with
other species.
The role of dystrophin in non-muscle tissue was
described by Tokarz et al. (1998) and Rafael et al.
(1999). In these reports, dystrophin expression was
investigated in non-muscle tissues of healthy mice
and detected in cardiac, kidney, and liver tissue. In
our investigation, we found expression of dys-
trophin 1 in normal liver tissue of dogs and cats,
whereas dystrophin 2 was not detectable. We were
unable to detect expression of y-sarcoglycan in
healthy liver tissues of dogs or cats. In contrast to
our observations, Noguchi et al. (2001) described
y-sarcoglycan expression in non-muscle tissues in
transgenic mice.
In chronic degenerative liver tissue, we found
altered expression of β-dystroglycan and dys-
trophin 1, compared with normal liver tissue. Be-
dossa et al. (2002) described similar results, when
they investigated hepatic stellate cells. They found
increased expression of β-dystroglycan in cases of
liver fibrosis. We found increased expression of β-
dystroglycan and dystrophin 1 on liver cell surfaces
and on perisinusoidal Ito cells. Hepatic stellate cells
or Ito cells are located perisinusoidally and trans-
form into fibroblastic cells in cases of liver fibrosis
(Schmitt-Graff et al., 1993). 
Liver fibrosis is a pathological process follow-
ing chronic liver disease. Many investigators have
described the role of Ito cells in the development
of liver fibrosis (Tanaka et al., 1991; Tang et al.,
1994; Nanni et al., 1995). Our results indicate that
the increased expression of β-dystroglycan and dy-
strophin 1 could be a sign of stellate cell activation
or cell metamorphosis in cases of early fibrosis.
Currently, there is no explanation for the absence
of y-sarcoglycan and dystrophin 2 expression. We
also found no correlation between the degree of de-
generation and the degree of protein expression in
this study. Because of a small number of animals
investigated, more should be investigated in future
studies to confirm these results. 
In conclusion, we found mild expression of
some DAGP in normal liver tissue in dogs and cats.
In chronic degenerative liver disease, the expres-
sion of some DAGP (β dystroglycan and dys-
trophin 1) was increased. We suggest that this cell
activation is the first step in liver fibrosis as a con-
sequence of degenerative liver disease in dogs and
cats. Further investigation is necessary to explain
the steps between degenerative liver disease and
liver fibrosis.
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